Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), caught up with Proactive's Andrew Scott to run through the latest on their Phase III Lupuzor study, results of which are due by the end of this quarter, as well as adding further detail to their ‘follow-up’ study which will allow eligible patients to continue to receive Lupuzor for another six months.
The results will be gathered as an ‘extension’ open label study – i.e. patients will know that they’re taking the drug – and will be independent of the original late-stage trial.
McCarthy also discusses the strong backing they received from existing and new institutional investors for their £10mln City fundraiser.
He says the cash will support future investment in the P140 peptide platform and will also be used to meet working capital requirements.